Velarion · Company Intelligence
Compensation Brief
Fiscal year 2022 · Filings through 2026-07-29

Cerevel Therapeutics Holdings (CERE)

CEO N. Anthony Coles was paid $11,225,426 in fiscal year 2022, ↑ up 38.4% from fiscal year 2021, the 86th percentile of its disclosed peer group (SEC filing 0000950170-23-015766 ↗): executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.

$11,225,426 ↑
N. Anthony Coles total, FY2022
86th
CEO pay percentile vs peers
35:1
CEO-to-median pay ratio
99.59%
Say-on-pay support, latest vote

Track this company's pay every filing: join the Pro seat waitlist

Velarion Pro: every company page, peer tools and exports, one seat — $1,200/year

A confirmation now and one email when Pro opens, and nothing else. Privacy

01

Summary Compensation Table — fiscal year 2022

Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
N. Anthony Coles$642,735$0$0$10,085,985$496,706$0$0$11,225,426
Chief Executive Officer and Chairperson of the Board of Directors
Raymond Sanchez498,120003,999,979288,711018,3004,805,110
Chief Medical Officer
John Renger482,052003,999,979279,398018,3004,779,729
Chief Scientific Officer
Abraham Ceesay511,651002,849,987296,553018,3003,676,491
President
Mark Bodenrader337,7120499,994587,480140,154018,3001,583,640
Interim Chief Financial Officer; Senior Vice President, Finance and Chief Accounting Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2022 totalFY2021 totalFY2020 totalΔ FY2021→2022
N. Anthony Coles$11,225,426$8,108,335$2,741,999↑ +3,117,091
Raymond Sanchez4,805,1103,416,2871,771,937↑ +1,388,823
John Renger4,779,7293,093,7501,845,075↑ +1,685,979
Abraham Ceesay3,676,4915,276,631—↓ −1,600,140
Mark Bodenrader1,583,6401,312,994—↑ +270,646

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

You have just read Cerevel Therapeutics Holdings's Summary Compensation Table. The whole free brief as a PDF, emailed now, with every figure cited — then a few short notes on the deeper CERE reports.

We send the PDF right away, then up to three short notes. Reply “unsubscribe” to any of them, any time.

How we handle your data → Privacy

Companies that benchmark against CERE
5 companies name CERE as a compensation peer

The list of companies that name CERE as a peer is temporarily unavailable — recheck shortly.

02

Equity transactions since the proxy statement was filed

Every insider equity transaction reported on Form 4 after the 2022 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
PERCEPTIVE ADVISORS LLCDirector2023-10-16A876,808$23$19,999,990CommonForm 4 ↗
BAIN CAPITAL INVESTORS LLCGreater-than-10% holder2023-10-16A5,480,05223124,999,986Common, indirectForm 4 ↗
Adam KoppelDirector2023-10-16A5,480,05223124,999,986Common, indirectForm 4 ↗
Christopher R. GordonDirector2023-10-16A5,480,05223124,999,986Common, indirectForm 4 ↗
Deval L. PatrickDirector2023-11-01D30,13000Derivative, Class A CommonForm 4 ↗
Deval L. PatrickDirector2023-11-01D30,13025753,250CommonForm 4 ↗
Deval L. PatrickDirector2023-11-01A30,13013380,241CommonForm 4 ↗
N. Anthony ColesDirector2023-11-02D38,59925972,239CommonForm 4 ↗
N. Anthony ColesDirector2023-11-02D38,59900Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-02A38,5994135,097CommonForm 4 ↗
N. Anthony ColesDirector2023-11-03D61,401251,561,458CommonForm 4 ↗
N. Anthony ColesDirector2023-11-03A61,4014214,904CommonForm 4 ↗
N. Anthony ColesDirector2023-11-03D61,40100Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-07D27,07600Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-07D27,07625677,555CommonForm 4 ↗
N. Anthony ColesDirector2023-11-07A27,076494,766CommonForm 4 ↗
Dividend-equivalent accruals2023-11-08—100——1 insider, 1 accrual row
N. Anthony ColesDirector2023-11-08A1004350CommonForm 4 ↗
N. Anthony ColesDirector2023-11-08D100252,516CommonForm 4 ↗
N. Anthony ColesDirector2023-11-14D22,82425573,455CommonForm 4 ↗
N. Anthony ColesDirector2023-11-14D22,82400Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-14A22,824479,884CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-05D7,50000Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-05D7,50035262,500CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-05A7,5001398,775CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-07D10,00000Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-07D10,00041413,700CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-07A10,00013131,700CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-07D10,00000Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-07D10,00041413,700CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-07A10,000435,000CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-15D7,50000Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-15D7,50041310,393CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-15A7,5001074,100CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19D5,08500Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19D14,19900Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19A5,085——CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-19D13,80400Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-19A13,804——CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2023-12-19D30,72100Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2023-12-19A30,721——CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-19D24,82500Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-19A24,825——CommonForm 4 ↗
Ronald C. Renaud JRDirector2023-12-19D160,45200Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2023-12-19A160,452——CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-19D13,79600Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-19A13,796——CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-19D13,91300Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-19A13,913——CommonForm 4 ↗
Paul D. BurgessSee Remarks2023-12-19D23,84700Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2023-12-19A23,847——CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19A14,199——CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-20D7,88941326,788CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-20D6,28841260,469CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2023-12-20D13,80841571,972CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-20D10,15241420,528CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-20D7,07241292,945CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-20D6,25641259,144CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-22D8,00000Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-22D8,00041331,608CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-22A8,000428,000CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-26D10,00000Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-26D10,00042424,700CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-26A10,000435,000CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-26D3,15000Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-26A3,1501031,658CommonForm 4 ↗
N. Anthony ColesDirector2024-01-02D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-01-02D50,000422,111,815CommonForm 4 ↗
N. Anthony ColesDirector2024-01-02A50,0004175,000CommonForm 4 ↗
John RengerChief Scientific Officer2024-01-19A87,57300Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-01-19A59,17100Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-01-19A284,02300Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-01-19A87,57300Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-01-19A81,06500Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2024-01-19A24,85200Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-01-19A63,90500Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-01-19A59,17100Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-01-19A81,06500Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-02-06D15,44000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-02-06A15,440——CommonForm 4 ↗
John RengerChief Scientific Officer2024-02-06D5,02000Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-02-06A5,020——CommonForm 4 ↗
N. Anthony ColesDirector2024-02-07D2,50642104,110CommonForm 4 ↗
John RengerChief Scientific Officer2024-02-07D2,1614289,777CommonForm 4 ↗
PERCEPTIVE ADVISORS LLCDirector2024-02-20D170,31700CommonForm 4 ↗
N. Anthony ColesDirector2024-02-29D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-02-29A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-02-29D50,000412,057,890CommonForm 4 ↗
N. Anthony ColesDirector2024-03-04D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-03-04D50,000412,050,550CommonForm 4 ↗
N. Anthony ColesDirector2024-03-04A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-04-01D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-04-01D50,000422,116,640CommonForm 4 ↗
N. Anthony ColesDirector2024-04-01A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-05-10D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-05-10D50,000422,105,125CommonForm 4 ↗
N. Anthony ColesDirector2024-05-10A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-06-03D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-06-03A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-06-03D50,000412,030,520CommonForm 4 ↗
Ruth MckernanDirector2024-06-05A10,461——CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-06-05A10,461——CommonForm 4 ↗
Douglas E. GiordanoDirector2024-06-05A10,461——CommonForm 4 ↗
Norbert G. RiedelDirector2024-06-05A10,461——CommonForm 4 ↗
Deval L. PatrickDirector2024-06-05A10,461——CommonForm 4 ↗
Marijn E. DekkersDirector2024-06-05A10,461——CommonForm 4 ↗
Adam KoppelDirector2024-06-05A10,461——CommonForm 4 ↗
N. Anthony ColesDirector2024-06-05A10,290——CommonForm 4 ↗
Christopher R. GordonDirector2024-06-05A10,461——CommonForm 4 ↗
N. Anthony ColesDirector2024-07-01D25,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-07-01D25,000411,029,535CommonForm 4 ↗
N. Anthony ColesDirector2024-07-01A25,000487,500CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D46,32200Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D4,809,418——Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D10,290——CommonForm 4 ↗
Mark BodenraderSee Remarks2024-08-01D24,85200Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2024-08-01D277,817——Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2024-08-01D17,724——CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D87,57300Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D15,06100Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D778,418——Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D6,370——CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D15,638——CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-08-01D81,06500Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-08-01D95,931——Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-08-01D45,727——CommonForm 4 ↗
Deval L. PatrickDirector2024-08-01D49,794——Derivative, Class A CommonForm 4 ↗
Deval L. PatrickDirector2024-08-01D10,461——CommonForm 4 ↗
Deval L. PatrickDirector2024-08-01D3,282——CommonForm 4 ↗
Norbert G. RiedelDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Norbert G. RiedelDirector2024-08-01D10,461——CommonForm 4 ↗
Norbert G. RiedelDirector2024-08-01D46,092——CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-08-01D81,06500Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-08-01D124,168——Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-08-01D16,913——CommonForm 4 ↗
Marijn E. DekkersDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Marijn E. DekkersDirector2024-08-01D402,326——Common, indirectForm 4 ↗
Marijn E. DekkersDirector2024-08-01D10,461——CommonForm 4 ↗
Marijn E. DekkersDirector2024-08-01D31,822——CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-08-01D59,17100Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-08-01D614,428——Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-08-01D10,666——CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-08-01D63,90500Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-08-01D711,827——Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-08-01D25,042——CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-08-01D10,461——CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-08-01D48,415——CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-08-01D59,17100Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-08-01D367,126——Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-08-01D7,527——CommonForm 4 ↗
Ruth MckernanDirector2024-08-01D92,986——Derivative, Class A CommonForm 4 ↗
Ruth MckernanDirector2024-08-01D10,461——CommonForm 4 ↗
Ruth MckernanDirector2024-08-01D3,282——CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D320,74200Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D284,02300Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D215,749——Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D83,857——CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D160,452——CommonForm 4 ↗
Douglas E. GiordanoDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Douglas E. GiordanoDirector2024-08-01D10,461——CommonForm 4 ↗
Douglas E. GiordanoDirector2024-08-01D3,282——CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-08-01D87,57300Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-08-01D1,393,153——Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-08-01D14,673——CommonForm 4 ↗
Adam KoppelDirector2024-08-01D80,189——Derivative, Class A CommonForm 4 ↗
Adam KoppelDirector2024-08-01D65,679,781——Common, indirectForm 4 ↗
Adam KoppelDirector2024-08-01D10,461——CommonForm 4 ↗
Adam KoppelDirector2024-08-01D3,282——CommonForm 4 ↗
Christopher R. GordonDirector2024-08-01D80,189——Derivative, Class A CommonForm 4 ↗
Christopher R. GordonDirector2024-08-01D65,679,781——Common, indirectForm 4 ↗
Christopher R. GordonDirector2024-08-01D10,461——CommonForm 4 ↗
Christopher R. GordonDirector2024-08-01D3,282——CommonForm 4 ↗
BAIN CAPITAL INVESTORS LLCDirector2024-08-01D65,679,781——Common, indirectForm 4 ↗
PFIZER INC—2024-08-01D27,349,211451,230,714,495CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

View all 175 transactions
InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
PERCEPTIVE ADVISORS LLCDirector2023-10-16A876,808$23$19,999,990CommonForm 4 ↗
BAIN CAPITAL INVESTORS LLCGreater-than-10% holder2023-10-16A5,480,05223124,999,986Common, indirectForm 4 ↗
Adam KoppelDirector2023-10-16A5,480,05223124,999,986Common, indirectForm 4 ↗
Christopher R. GordonDirector2023-10-16A5,480,05223124,999,986Common, indirectForm 4 ↗
Deval L. PatrickDirector2023-11-01D30,13000Derivative, Class A CommonForm 4 ↗
Deval L. PatrickDirector2023-11-01D30,13025753,250CommonForm 4 ↗
Deval L. PatrickDirector2023-11-01A30,13013380,241CommonForm 4 ↗
N. Anthony ColesDirector2023-11-02D38,59925972,239CommonForm 4 ↗
N. Anthony ColesDirector2023-11-02D38,59900Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-02A38,5994135,097CommonForm 4 ↗
N. Anthony ColesDirector2023-11-03D61,401251,561,458CommonForm 4 ↗
N. Anthony ColesDirector2023-11-03A61,4014214,904CommonForm 4 ↗
N. Anthony ColesDirector2023-11-03D61,40100Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-07D27,07600Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-07D27,07625677,555CommonForm 4 ↗
N. Anthony ColesDirector2023-11-07A27,076494,766CommonForm 4 ↗
N. Anthony ColesDirector2023-11-08D10000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-08A1004350CommonForm 4 ↗
N. Anthony ColesDirector2023-11-08D100252,516CommonForm 4 ↗
N. Anthony ColesDirector2023-11-14D22,82425573,455CommonForm 4 ↗
N. Anthony ColesDirector2023-11-14D22,82400Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2023-11-14A22,824479,884CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-05D7,50000Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-05D7,50035262,500CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-05A7,5001398,775CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-07D10,00000Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-07D10,00041413,700CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-07A10,00013131,700CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-07D10,00000Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-07D10,00041413,700CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-07A10,000435,000CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-15D7,50000Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-15D7,50041310,393CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-15A7,5001074,100CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19D5,08500Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19D14,19900Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19A5,085——CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-19D13,80400Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-19A13,804——CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2023-12-19D30,72100Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2023-12-19A30,721——CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-19D24,82500Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-19A24,825——CommonForm 4 ↗
Ronald C. Renaud JRDirector2023-12-19D160,45200Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2023-12-19A160,452——CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-19D13,79600Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-19A13,796——CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-19D13,91300Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-19A13,913——CommonForm 4 ↗
Paul D. BurgessSee Remarks2023-12-19D23,84700Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2023-12-19A23,847——CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-19A14,199——CommonForm 4 ↗
Mark BodenraderSee Remarks2023-12-20D7,88941326,788CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-20D6,28841260,469CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2023-12-20D13,80841571,972CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-20D10,15241420,528CommonForm 4 ↗
Scott AkamineChief Legal Officer2023-12-20D7,07241292,945CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-20D6,25641259,144CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-22D8,00000Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-22D8,00041331,608CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2023-12-22A8,000428,000CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-26D10,00000Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-26D10,00042424,700CommonForm 4 ↗
Raymond SanchezChief Medical Officer2023-12-26A10,000435,000CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-26D3,15000Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2023-12-26A3,1501031,658CommonForm 4 ↗
N. Anthony ColesDirector2024-01-02D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-01-02D50,000422,111,815CommonForm 4 ↗
N. Anthony ColesDirector2024-01-02A50,0004175,000CommonForm 4 ↗
John RengerChief Scientific Officer2024-01-19A87,57300Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-01-19A59,17100Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-01-19A284,02300Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-01-19A87,57300Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-01-19A81,06500Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2024-01-19A24,85200Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-01-19A63,90500Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-01-19A59,17100Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-01-19A81,06500Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-02-06D15,44000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-02-06A15,440——CommonForm 4 ↗
John RengerChief Scientific Officer2024-02-06D5,02000Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-02-06A5,020——CommonForm 4 ↗
N. Anthony ColesDirector2024-02-07D2,50642104,110CommonForm 4 ↗
John RengerChief Scientific Officer2024-02-07D2,1614289,777CommonForm 4 ↗
PERCEPTIVE ADVISORS LLCDirector2024-02-20D170,31700CommonForm 4 ↗
N. Anthony ColesDirector2024-02-29D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-02-29A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-02-29D50,000412,057,890CommonForm 4 ↗
N. Anthony ColesDirector2024-03-04D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-03-04D50,000412,050,550CommonForm 4 ↗
N. Anthony ColesDirector2024-03-04A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-04-01D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-04-01D50,000422,116,640CommonForm 4 ↗
N. Anthony ColesDirector2024-04-01A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-05-10D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-05-10D50,000422,105,125CommonForm 4 ↗
N. Anthony ColesDirector2024-05-10A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-06-03D50,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-06-03A50,0004175,000CommonForm 4 ↗
N. Anthony ColesDirector2024-06-03D50,000412,030,520CommonForm 4 ↗
Ruth MckernanDirector2024-06-05A10,461——CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-06-05A10,461——CommonForm 4 ↗
Douglas E. GiordanoDirector2024-06-05A10,461——CommonForm 4 ↗
Norbert G. RiedelDirector2024-06-05A10,461——CommonForm 4 ↗
Deval L. PatrickDirector2024-06-05A10,461——CommonForm 4 ↗
Marijn E. DekkersDirector2024-06-05A10,461——CommonForm 4 ↗
Adam KoppelDirector2024-06-05A10,461——CommonForm 4 ↗
N. Anthony ColesDirector2024-06-05A10,290——CommonForm 4 ↗
Christopher R. GordonDirector2024-06-05A10,461——CommonForm 4 ↗
N. Anthony ColesDirector2024-07-01D25,00000Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-07-01D25,000411,029,535CommonForm 4 ↗
N. Anthony ColesDirector2024-07-01A25,000487,500CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D46,32200Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D4,809,418——Derivative, Class A CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D10,290——CommonForm 4 ↗
Mark BodenraderSee Remarks2024-08-01D24,85200Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2024-08-01D277,817——Derivative, Class A CommonForm 4 ↗
Mark BodenraderSee Remarks2024-08-01D17,724——CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D87,57300Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D15,06100Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D778,418——Derivative, Class A CommonForm 4 ↗
John RengerChief Scientific Officer2024-08-01D6,370——CommonForm 4 ↗
N. Anthony ColesDirector2024-08-01D15,638——CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-08-01D81,06500Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-08-01D95,931——Derivative, Class A CommonForm 4 ↗
Paul D. BurgessSee Remarks2024-08-01D45,727——CommonForm 4 ↗
Deval L. PatrickDirector2024-08-01D49,794——Derivative, Class A CommonForm 4 ↗
Deval L. PatrickDirector2024-08-01D10,461——CommonForm 4 ↗
Deval L. PatrickDirector2024-08-01D3,282——CommonForm 4 ↗
Norbert G. RiedelDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Norbert G. RiedelDirector2024-08-01D10,461——CommonForm 4 ↗
Norbert G. RiedelDirector2024-08-01D46,092——CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-08-01D81,06500Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-08-01D124,168——Derivative, Class A CommonForm 4 ↗
Susan ALTSCHULLERChief Financial Officer2024-08-01D16,913——CommonForm 4 ↗
Marijn E. DekkersDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Marijn E. DekkersDirector2024-08-01D402,326——Common, indirectForm 4 ↗
Marijn E. DekkersDirector2024-08-01D10,461——CommonForm 4 ↗
Marijn E. DekkersDirector2024-08-01D31,822——CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-08-01D59,17100Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-08-01D614,428——Derivative, Class A CommonForm 4 ↗
Kathleen TregoningSee Remarks2024-08-01D10,666——CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-08-01D63,90500Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-08-01D711,827——Derivative, Class A CommonForm 4 ↗
Kenneth DiPietroChief Human Resources Officer2024-08-01D25,042——CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-08-01D10,461——CommonForm 4 ↗
Gabrielle SulzbergerDirector2024-08-01D48,415——CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-08-01D59,17100Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-08-01D367,126——Derivative, Class A CommonForm 4 ↗
Scott AkamineChief Legal Officer2024-08-01D7,527——CommonForm 4 ↗
Ruth MckernanDirector2024-08-01D92,986——Derivative, Class A CommonForm 4 ↗
Ruth MckernanDirector2024-08-01D10,461——CommonForm 4 ↗
Ruth MckernanDirector2024-08-01D3,282——CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D320,74200Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D284,02300Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D215,749——Derivative, Class A CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D83,857——CommonForm 4 ↗
Ronald C. Renaud JRDirector2024-08-01D160,452——CommonForm 4 ↗
Douglas E. GiordanoDirector2024-08-01D95,242——Derivative, Class A CommonForm 4 ↗
Douglas E. GiordanoDirector2024-08-01D10,461——CommonForm 4 ↗
Douglas E. GiordanoDirector2024-08-01D3,282——CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-08-01D87,57300Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-08-01D1,393,153——Derivative, Class A CommonForm 4 ↗
Raymond SanchezChief Medical Officer2024-08-01D14,673——CommonForm 4 ↗
Adam KoppelDirector2024-08-01D80,189——Derivative, Class A CommonForm 4 ↗
Adam KoppelDirector2024-08-01D65,679,781——Common, indirectForm 4 ↗
Adam KoppelDirector2024-08-01D10,461——CommonForm 4 ↗
Adam KoppelDirector2024-08-01D3,282——CommonForm 4 ↗
Christopher R. GordonDirector2024-08-01D80,189——Derivative, Class A CommonForm 4 ↗
Christopher R. GordonDirector2024-08-01D65,679,781——Common, indirectForm 4 ↗
Christopher R. GordonDirector2024-08-01D10,461——CommonForm 4 ↗
Christopher R. GordonDirector2024-08-01D3,282——CommonForm 4 ↗
BAIN CAPITAL INVESTORS LLCDirector2024-08-01D65,679,781——Common, indirectForm 4 ↗
PFIZER INC—2024-08-01D27,349,211451,230,714,495CommonForm 4 ↗
03

Grants of plan-based awards — fiscal year 2022

ExecutiveAwardGrant dateThresholdTargetGrantedMaximumGrant-date fair value
Mark BodenraderOPTION2022-02-09——24,800—$587,480
Mark BodenraderRSU2022-06-01——18,932—499,994
Raymond SanchezOPTION2022-02-09——168,856—3,999,979
Abraham CeesayOPTION2022-02-09——120,310—2,849,987
John RengerOPTION2022-02-09——168,856—3,999,979
N. AnthonyOPTION2022-02-09——425,772—10,085,985
03b

Vehicle mix — grant-date fair value by award type

Named executive officerTime-vested (RSU)Performance-vested (PSU)Options / SARs% performance-vested
Mark Bodenrader$499,994$0$587,4800.0%
Raymond Sanchez003,999,9790.0%
Abraham Ceesay002,849,9870.0%
John Renger003,999,9790.0%
N. Anthony0010,085,9850.0%

% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.

04

Outstanding equity awards at fiscal year-end 2022

ExecutiveAwardShares unvestedExercise priceMarket value unvested
Mark BodenraderRSU18,932—$597,115
N. Anthony ColesOption425,77230.36—
Raymond SanchezOption168,85630.36—
Raymond SanchezOption11,6353.5—
John RengerOption58,9019.88—
John RengerOption13,35810.28—
N. Anthony ColesOption396,88812.7—
N. Anthony ColesOption98,1689.88—
Mark BodenraderOption24,80030.36—
Mark BodenraderOption32,7239.88—
Mark BodenraderOption10,9073.5—
Raymond SanchezOption150,92912.7—
Raymond SanchezOption65,4459.88—
Raymond SanchezOption3,87810.28—
John RengerOption134,16012.7—
John RengerOption40,0733.5—
Abraham CeesayOption120,31030.36—
Abraham CeesayOption288,16613.17—
Mark BodenraderOption48,75012.7—
John RengerOption168,85630.36—
Mark BodenraderOption3,63610.28—
05

Incentive-plan design — the Compensation Discussion & Analysis

Our executive compensation programs are designed to motivate, retain and reward high-performing executives for their long-term value creation for the Company. While we consider several factors in our pay structure, we are guided by the following core philosophies and principles: Mission and Patient Focused, Pay for Performance, Alignment with Stockholders, Simplicity and Transparency, Program Consistency.

CEO STI target (% of salary)60%
CEO LTI target (% of salary)—
Independent consultantPay Governance LLC
Clawback policyTrue
Anti-hedgingTrue
Anti-pledgingTrue
06

Say-on-pay — recent advisory votes

Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20232023-06-07148,773,111606,1334,38199.59%Passed
20222022-06-14115,000,333388,15210,02499.66%Passed
20212021-06-10—————
20202020-10-26—————

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.

Say-on-pay — history, company's computation

Meeting yearMeeting dateApproval — company's computation
20232023-06-0799.59%a
20222022-06-1499.66%b
20212021-06-10—c

a. Approved under the standard stated in the filing — “Abstentions and broker non-votes will have no effect on the outcome of this vote.”.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

07

CEO pay ratio

Ratio (CEO : median employee)35 : 1
CEO total compensation$11,225,426
Median employee compensation—
08

Director compensation — fiscal year 2022

DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Norbert Riedel, Ph.DIndependent · Lead Independent Director · Audit · Science and Technology (Chair)$134,582$0$427,984—$0$562,566
Gabrielle Sulzberger, J.D., M.B.AIndependent · Audit (Chair) · Nominating/Governance82,9990427,984—0510,983
Marijn Dekkers, Ph.DIndependent · Compensation · Nominating/Governance71,3330427,984—0499,317
Doug Giordano, M.B.AIndependent · Audit · Compensation (Chair)69,1660427,984—0497,150
Christopher Gordon, M.B.AIndependent · Nominating/Governance (Chair)69,1660427,984—0497,150
Adam Koppel, M.D., Ph.DIndependent · Compensation · Science and Technology65,0000427,984—0492,984
Ruth McKernan, Ph.D., CBE, FMedSciIndependent · Science and Technology57,5000427,984—0485,484
Deval Patrick, J.DIndependent · Compensation57,5000427,984—0485,484
Suneet Varma, M.B.ANot independent · Science and Technology · Newly elected000—00
Deborah Baron, M.B.AIndependent · Nominating/Governance000—00
N. Anthony Coles, M.DEmployee director · Board Chair000—00
Morris Birnbaum, M.D., Ph.DNot independent · Departed during FY000—00
09

Board fee structure and ownership guideline

Annual cash retainer$50,000
Annual equity retainer$428,000
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 15,000 / 15,000
Stock ownership guideline3x annual cash retainer
09b

Total cost of the board

ComponentFY2022
Cash retainers and fees$607,246
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$607,246

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

10

Disclosed peer group — fiscal year 2022

The compensation peer group as the company disclosed it in its own proxy — the reference set behind the percentile above.

10a

Peer reciprocity

Of the companies Cerevel Therapeutics Holdings names as compensation peers, which name it back in their own disclosed peer groups. A peer set the market reciprocates reads differently from one selected in a single direction.

Reciprocity shown where the peer's own current proxy has been read — each mark is cited in the register to that peer's filing. A dash means the peer's current proxy was read and names no reciprocal group including Cerevel Therapeutics Holdings.

10b

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1BridgeBio Pharma2025Neil Kumar$1,044,000$10,606,275$1,874,992$0$14,944,585
2Neurocrine Biosciences2025Kyle Gano920,0005,750,0235,750,006013,448,935
3Cerevel Therapeutics Holdings2022N. Anthony Coles642,735010,085,985496,70611,225,426
4Karuna Therapeutics2022Steven Paul700,00009,905,953609,00011,224,103
5Axsome Therapeutics2025Herriot Tabuteau835,0005,533,5542,833,237876,75010,283,492
6Arcus Biosciences2025Terry Rosen775,0002,199,4506,008,860658,7509,656,813
7Sage Therapeutics2024Barry Greene830,7123,164,3642,669,263431,9707,112,589
8Arvinas2025John Houston706,2362,685,8402,671,051457,0006,534,127
9Allogene Therapeutics2025David Chang724,0002,409,5372,588,329400,0106,136,093
10Replimune Group2026Sushil Patel700,0003,376,0031,448,325315,0005,845,982
11Zymeworks2024Kenneth Galbraith654,8332,112,0001,985,672361,6525,253,616
12Intellia Therapeutics2025John Leonard708,0002,443,9201,356,32005,063,899
13Denali Therapeutics2025Ryan Watts718,0001,151,8672,180,00304,751,515
14Fate Therapeutics2025Bahram Valamehr600,00001,283,868360,0002,248,568
15Alector2025Arnon Rosenthal678,100422,876558,216325,4881,995,018

Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

10c

Incentive design against the same peers

CompanyAnnual incentive payoutLong-term vehicle mixPSU measures include TSRCompensation consultant
Cerevel Therapeutics Holdings128.8%Options 100not disclosedPay Governance LLC
Alector80%not disclosednot disclosedPearl Meyer & Partners, LLC
Allogene Therapeuticsnot disclosedOption 55 · RSU 25 · PSU 20not disclosedCompensia
Arcus Biosciences100%Options 67 · RSU 33not disclosedRadford
Arvinas108%Options 50 · RSU 50not disclosedAon (Aon's Human Capital Solutions practice, a division of Aon plc)
Axsome Therapeutics150%RSU 33 · Options 33 · PSU 33NoFrederic W. Cook & Co., Inc.
BridgeBio Pharma135%RSU 50 · PSU 35 · Options 15NoAon Talent Solutions
Denali Therapeutics145%not disclosednot disclosedAlpine Rewards
Fate Therapeutics100%Options 100NoAon's Human Capital Solutions practice (Radford)
Intellia Therapeutics115%Option 40 · RSU 40 · PSU 20Yes — TSR relative to the Nasdaq Biotechnology IndexAlpine
Karuna Therapeutics145%Option 100not disclosedAon
Neurocrine Biosciences105%Options 50 · PSU 30 · RSU 20NoFrederic W. Cook & Co., Inc.
Replimune Groupnot disclosednot disclosedNoPearl Meyer
Sage Therapeutics80%not disclosedYes — TSR milestones / Relative TSR vs. Nasdaq Biotechnology IndexAlpine Rewards
Zymeworksnot disclosedOption 50 · RSU 50not disclosedAon plc

Read from each company's Compensation Discussion and Analysis: annual incentive payout as a percentage of target, the disclosed long-term vehicle mix, whether performance-share measures include a total shareholder return component, and the retained compensation consultant. “Not disclosed” appears only where the company's filing does not state the item.

10d

Frequently asked questions

Who was the highest-paid executive at Cerevel Therapeutics Holdings in fiscal 2022?
As disclosed, N. Anthony Coles (Chief Executive Officer and Chairperson of the Board of Directors) was the highest-paid executive at Cerevel Therapeutics Holdings in fiscal 2022, with total compensation of $11,225,426.
How does Cerevel Therapeutics Holdings's chief executive pay compare to its disclosed peer group?
As disclosed, N. Anthony Coles's total compensation ranked at the 86th percentile of Cerevel Therapeutics Holdings's disclosed peer group.
What is Cerevel Therapeutics Holdings's CEO-to-median employee pay ratio?
As disclosed, Cerevel Therapeutics Holdings's CEO-to-median employee pay ratio was 35:1.
How did shareholders vote on Cerevel Therapeutics Holdings's executive compensation?
As disclosed, 99.59% of shareholders supported Cerevel Therapeutics Holdings's executive compensation in the latest say-on-pay vote.
How much does Cerevel Therapeutics Holdings spend in total on board compensation for fiscal 2022?
As disclosed, Cerevel Therapeutics Holdings reported total board compensation of $607,246 for fiscal 2022.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

11

Source register

Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.

#SupportsDocumentFiledAccessionLocation in document
1Section 01, N. Anthony ColesDEF 14A2023-04-280000950170-23-015766Section “Summary Compensation Table” · page 33. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016
2Section 01, Raymond SanchezDEF 14A2023-04-280000950170-23-015766Section “Summary Compensation Table” · page 33. As printed: 4,805,110. Filing ↗machine: t23 · r10 · c29 · span 1103210–1103219
3Section 01, John RengerDEF 14A2023-04-280000950170-23-015766Section “Summary Compensation Table” · page 33. As printed: 4,779,729. Filing ↗machine: t23 · r13 · c29 · span 1141102–1141111
4Section 01, Abraham CeesayDEF 14A2023-04-280000950170-23-015766Section “Summary Compensation Table” · page 33. As printed: 3,676,491. Filing ↗machine: t23 · r16 · c29 · span 1178948–1178957
5Section 01, Mark BodenraderDEF 14A2023-04-280000950170-23-015766Section “Summary Compensation Table” · page 33. As printed: 1,583,640. Filing ↗machine: t23 · r5 · c29 · span 1048197–1048206
6Section 03, Mark Bodenrader OPTIONDEF 14A2023-04-280000950170-23-015766Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r6 · c18 · span 1267635–1267641
7Section 03, Mark Bodenrader RSUDEF 14A2023-04-280000950170-23-015766Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r7 · c14 · span 1277372–1277378
8Section 03, Raymond Sanchez OPTIONDEF 14A2023-04-280000950170-23-015766Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r9 · c18 · span 1302066–1302073
9Section 03, Abraham Ceesay OPTIONDEF 14A2023-04-280000950170-23-015766Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r13 · c18 · span 1348242–1348249
10Section 03, John Renger OPTIONDEF 14A2023-04-280000950170-23-015766Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r11 · c18 · span 1325152–1325159
11Section 03, N. Anthony OPTIONDEF 14A2023-04-280000950170-23-015766Section “Grants of Plan-Based Awards” · grants of plan-based awards table. Filing ↗machine: t24 · r4 · c18 · span 1244551–1244558
12Section 07, pay ratioDEF 14A—0000950170-23-015766Section “CEO Pay Ratio”. As printed: 35 : 1.machine: t5 · r47 · c1 · span 149425–149427
13Section 08, Norbert Riedel, Ph.DDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 562,566. Filing ↗machine: t34 · r10 · c12 · span 2178895–2179234
14Section 08, Gabrielle Sulzberger, J.D., M.B.ADEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 510,983. Filing ↗machine: t34 · r11 · c12 · span 2184797–2185136
15Section 08, Marijn Dekkers, Ph.DDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 499,317. Filing ↗machine: t34 · r4 · c12 · span 2143541–2143880
16Section 08, Doug Giordano, M.B.ADEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 497,150. Filing ↗machine: t34 · r5 · c12 · span 2149430–2149769
17Section 08, Christopher Gordon, M.B.ADEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 497,150. Filing ↗machine: t34 · r6 · c12 · span 2155324–2155663
18Section 08, Adam Koppel, M.D., Ph.DDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 492,984. Filing ↗machine: t34 · r7 · c12 · span 2161216–2161555
19Section 08, Ruth McKernan, Ph.D., CBE, FMedSciDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 485,484. Filing ↗machine: t34 · r8 · c12 · span 2167118–2167457
20Section 08, Deval Patrick, J.DDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 485,484. Filing ↗machine: t34 · r9 · c12 · span 2173005–2173344
21Section 08, Suneet Varma, M.B.ADEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 0. Filing ↗
22Section 08, Deborah Baron, M.B.ADEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 0. Filing ↗
23Section 08, N. Anthony Coles, M.DDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 0. Filing ↗
24Section 08, Morris Birnbaum, M.D., Ph.DDEF 14A2023-04-280000950170-23-015766Section “Director Compensation”. As printed: 0. Filing ↗
25Section 02, PERCEPTIVE ADVISORS LLC 2023-10-16Form 42023-10-170001062993-23-019470Insider equity transaction reported since the proxy statement. Filing ↗
26Section 02, BAIN CAPITAL INVESTORS LLC 2023-10-16Form 42023-10-180000899243-23-019969Insider equity transaction reported since the proxy statement. Filing ↗
27Section 02, Adam Koppel 2023-10-16Form 42023-10-180000899243-23-019971Insider equity transaction reported since the proxy statement. Filing ↗
28Section 02, Christopher R. Gordon 2023-10-16Form 42023-10-180000899243-23-019970Insider equity transaction reported since the proxy statement. Filing ↗
29Section 02, Deval L. Patrick 2023-11-01Form 42023-11-030000950170-23-058836Insider equity transaction reported since the proxy statement. Filing ↗
30Section 02, Deval L. Patrick 2023-11-01Form 42023-11-030000950170-23-058836Insider equity transaction reported since the proxy statement. Filing ↗
31Section 02, Deval L. Patrick 2023-11-01Form 42023-11-030000950170-23-058836Insider equity transaction reported since the proxy statement. Filing ↗
32Section 02, N. Anthony Coles 2023-11-02Form 42023-11-060000950170-23-059520Insider equity transaction reported since the proxy statement. Filing ↗
33Section 02, N. Anthony Coles 2023-11-02Form 42023-11-060000950170-23-059520Insider equity transaction reported since the proxy statement. Filing ↗
34Section 02, N. Anthony Coles 2023-11-02Form 42023-11-060000950170-23-059520Insider equity transaction reported since the proxy statement. Filing ↗
35Section 02, N. Anthony Coles 2023-11-03Form 42023-11-060000950170-23-059520Insider equity transaction reported since the proxy statement. Filing ↗
36Section 02, N. Anthony Coles 2023-11-03Form 42023-11-060000950170-23-059520Insider equity transaction reported since the proxy statement. Filing ↗
37Section 02, N. Anthony Coles 2023-11-03Form 42023-11-060000950170-23-059520Insider equity transaction reported since the proxy statement. Filing ↗
38Section 02, N. Anthony Coles 2023-11-07Form 42023-11-090000950170-23-062217Insider equity transaction reported since the proxy statement. Filing ↗
39Section 02, N. Anthony Coles 2023-11-07Form 42023-11-090000950170-23-062217Insider equity transaction reported since the proxy statement. Filing ↗
40Section 02, N. Anthony Coles 2023-11-07Form 42023-11-090000950170-23-062217Insider equity transaction reported since the proxy statement. Filing ↗
41Section 02, N. Anthony Coles 2023-11-08Form 42023-11-090000950170-23-062217Insider equity transaction reported since the proxy statement. Filing ↗
42Section 02, N. Anthony Coles 2023-11-08Form 42023-11-090000950170-23-062217Insider equity transaction reported since the proxy statement. Filing ↗
43Section 02, N. Anthony Coles 2023-11-08Form 42023-11-090000950170-23-062217Insider equity transaction reported since the proxy statement. Filing ↗
44Section 02, N. Anthony Coles 2023-11-14Form 42023-11-160000950170-23-064517Insider equity transaction reported since the proxy statement. Filing ↗
45Section 02, N. Anthony Coles 2023-11-14Form 42023-11-160000950170-23-064517Insider equity transaction reported since the proxy statement. Filing ↗
46Section 02, N. Anthony Coles 2023-11-14Form 42023-11-160000950170-23-064517Insider equity transaction reported since the proxy statement. Filing ↗
47Section 02, Scott Akamine 2023-12-05Form 42023-12-070000950170-23-068887Insider equity transaction reported since the proxy statement. Filing ↗
48Section 02, Scott Akamine 2023-12-05Form 42023-12-070000950170-23-068887Insider equity transaction reported since the proxy statement. Filing ↗
49Section 02, Scott Akamine 2023-12-05Form 42023-12-070000950170-23-068887Insider equity transaction reported since the proxy statement. Filing ↗
50Section 02, Scott Akamine 2023-12-07Form 42023-12-070000950170-23-068887Insider equity transaction reported since the proxy statement. Filing ↗
51Section 02, Scott Akamine 2023-12-07Form 42023-12-070000950170-23-068887Insider equity transaction reported since the proxy statement. Filing ↗
52Section 02, Scott Akamine 2023-12-07Form 42023-12-070000950170-23-068887Insider equity transaction reported since the proxy statement. Filing ↗
53Section 02, Raymond Sanchez 2023-12-07Form 42023-12-110000950170-23-069417Insider equity transaction reported since the proxy statement. Filing ↗
54Section 02, Raymond Sanchez 2023-12-07Form 42023-12-110000950170-23-069417Insider equity transaction reported since the proxy statement. Filing ↗
55Section 02, Raymond Sanchez 2023-12-07Form 42023-12-110000950170-23-069417Insider equity transaction reported since the proxy statement. Filing ↗
56Section 02, Raymond Sanchez 2023-12-15Form 42023-12-190000950170-23-071490Insider equity transaction reported since the proxy statement. Filing ↗
57Section 02, Raymond Sanchez 2023-12-15Form 42023-12-190000950170-23-071490Insider equity transaction reported since the proxy statement. Filing ↗
58Section 02, Raymond Sanchez 2023-12-15Form 42023-12-190000950170-23-071490Insider equity transaction reported since the proxy statement. Filing ↗
59Section 02, Mark Bodenrader 2023-12-19Form 42023-12-210000950170-23-072381Insider equity transaction reported since the proxy statement. Filing ↗
60Section 02, Mark Bodenrader 2023-12-19Form 42023-12-210000950170-23-072381Insider equity transaction reported since the proxy statement. Filing ↗
61Section 02, Mark Bodenrader 2023-12-19Form 42023-12-210000950170-23-072381Insider equity transaction reported since the proxy statement. Filing ↗
62Section 02, Kathleen Tregoning 2023-12-19Form 42023-12-210000950170-23-072363Insider equity transaction reported since the proxy statement. Filing ↗
63Section 02, Kathleen Tregoning 2023-12-19Form 42023-12-210000950170-23-072363Insider equity transaction reported since the proxy statement. Filing ↗
64Section 02, Susan ALTSCHULLER 2023-12-19Form 42023-12-210000950170-23-072368Insider equity transaction reported since the proxy statement. Filing ↗
65Section 02, Susan ALTSCHULLER 2023-12-19Form 42023-12-210000950170-23-072368Insider equity transaction reported since the proxy statement. Filing ↗
66Section 02, Raymond Sanchez 2023-12-19Form 42023-12-210000950170-23-072370Insider equity transaction reported since the proxy statement. Filing ↗
67Section 02, Raymond Sanchez 2023-12-19Form 42023-12-210000950170-23-072370Insider equity transaction reported since the proxy statement. Filing ↗
68Section 02, Ronald C. Renaud JR 2023-12-19Form 42023-12-210000950170-23-072374Insider equity transaction reported since the proxy statement. Filing ↗
69Section 02, Ronald C. Renaud JR 2023-12-19Form 42023-12-210000950170-23-072374Insider equity transaction reported since the proxy statement. Filing ↗
70Section 02, Scott Akamine 2023-12-19Form 42023-12-210000950170-23-072375Insider equity transaction reported since the proxy statement. Filing ↗
71Section 02, Scott Akamine 2023-12-19Form 42023-12-210000950170-23-072375Insider equity transaction reported since the proxy statement. Filing ↗
72Section 02, Kenneth DiPietro 2023-12-19Form 42023-12-210000950170-23-072377Insider equity transaction reported since the proxy statement. Filing ↗
73Section 02, Kenneth DiPietro 2023-12-19Form 42023-12-210000950170-23-072377Insider equity transaction reported since the proxy statement. Filing ↗
74Section 02, Paul D. Burgess 2023-12-19Form 42023-12-210000950170-23-072380Insider equity transaction reported since the proxy statement. Filing ↗
75Section 02, Paul D. Burgess 2023-12-19Form 42023-12-210000950170-23-072380Insider equity transaction reported since the proxy statement. Filing ↗
76Section 02, Mark Bodenrader 2023-12-19Form 42023-12-210000950170-23-072381Insider equity transaction reported since the proxy statement. Filing ↗
77Section 02, Mark Bodenrader 2023-12-20Form 42023-12-210000950170-23-072381Insider equity transaction reported since the proxy statement. Filing ↗
78Section 02, Kathleen Tregoning 2023-12-20Form 42023-12-210000950170-23-072363Insider equity transaction reported since the proxy statement. Filing ↗
79Section 02, Susan ALTSCHULLER 2023-12-20Form 42023-12-210000950170-23-072368Insider equity transaction reported since the proxy statement. Filing ↗
80Section 02, Raymond Sanchez 2023-12-20Form 42023-12-210000950170-23-072370Insider equity transaction reported since the proxy statement. Filing ↗
81Section 02, Scott Akamine 2023-12-20Form 42023-12-210000950170-23-072375Insider equity transaction reported since the proxy statement. Filing ↗
82Section 02, Kenneth DiPietro 2023-12-20Form 42023-12-210000950170-23-072377Insider equity transaction reported since the proxy statement. Filing ↗
83Section 02, Kenneth DiPietro 2023-12-22Form 42023-12-270000950170-23-073306Insider equity transaction reported since the proxy statement. Filing ↗
84Section 02, Kenneth DiPietro 2023-12-22Form 42023-12-270000950170-23-073306Insider equity transaction reported since the proxy statement. Filing ↗
85Section 02, Kenneth DiPietro 2023-12-22Form 42023-12-270000950170-23-073306Insider equity transaction reported since the proxy statement. Filing ↗
86Section 02, Raymond Sanchez 2023-12-26Form 42023-12-280000950170-23-073591Insider equity transaction reported since the proxy statement. Filing ↗
87Section 02, Raymond Sanchez 2023-12-26Form 42023-12-280000950170-23-073591Insider equity transaction reported since the proxy statement. Filing ↗
88Section 02, Raymond Sanchez 2023-12-26Form 42023-12-280000950170-23-073591Insider equity transaction reported since the proxy statement. Filing ↗
89Section 02, Kathleen Tregoning 2023-12-26Form 42023-12-280000950170-23-073592Insider equity transaction reported since the proxy statement. Filing ↗
90Section 02, Kathleen Tregoning 2023-12-26Form 42023-12-280000950170-23-073592Insider equity transaction reported since the proxy statement. Filing ↗
91Section 02, N. Anthony Coles 2024-01-02Form 42024-01-040000950170-24-001864Insider equity transaction reported since the proxy statement. Filing ↗
92Section 02, N. Anthony Coles 2024-01-02Form 42024-01-040000950170-24-001864Insider equity transaction reported since the proxy statement. Filing ↗
93Section 02, N. Anthony Coles 2024-01-02Form 42024-01-040000950170-24-001864Insider equity transaction reported since the proxy statement. Filing ↗
94Section 02, John Renger 2024-01-19Form 42024-01-230000950170-24-006704Insider equity transaction reported since the proxy statement. Filing ↗
95Section 02, Scott Akamine 2024-01-19Form 42024-01-230000950170-24-006666Insider equity transaction reported since the proxy statement. Filing ↗
96Section 02, Ronald C. Renaud JR 2024-01-19Form 42024-01-230000950170-24-006667Insider equity transaction reported since the proxy statement. Filing ↗
97Section 02, Raymond Sanchez 2024-01-19Form 42024-01-230000950170-24-006671Insider equity transaction reported since the proxy statement. Filing ↗
98Section 02, Paul D. Burgess 2024-01-19Form 42024-01-230000950170-24-006677Insider equity transaction reported since the proxy statement. Filing ↗
99Section 02, Mark Bodenrader 2024-01-19Form 42024-01-230000950170-24-006678Insider equity transaction reported since the proxy statement. Filing ↗
100Section 02, Kenneth DiPietro 2024-01-19Form 42024-01-230000950170-24-006692Insider equity transaction reported since the proxy statement. Filing ↗
101Section 02, Kathleen Tregoning 2024-01-19Form 42024-01-230000950170-24-006696Insider equity transaction reported since the proxy statement. Filing ↗
102Section 02, Susan ALTSCHULLER 2024-01-19Form 42024-01-230000950170-24-006706Insider equity transaction reported since the proxy statement. Filing ↗
103Section 02, N. Anthony Coles 2024-02-06Form 42024-02-080000950170-24-012953Insider equity transaction reported since the proxy statement. Filing ↗
104Section 02, N. Anthony Coles 2024-02-06Form 42024-02-080000950170-24-012953Insider equity transaction reported since the proxy statement. Filing ↗
105Section 02, John Renger 2024-02-06Form 42024-02-080000950170-24-012962Insider equity transaction reported since the proxy statement. Filing ↗
106Section 02, John Renger 2024-02-06Form 42024-02-080000950170-24-012962Insider equity transaction reported since the proxy statement. Filing ↗
107Section 02, N. Anthony Coles 2024-02-07Form 42024-02-080000950170-24-012953Insider equity transaction reported since the proxy statement. Filing ↗
108Section 02, John Renger 2024-02-07Form 42024-02-080000950170-24-012962Insider equity transaction reported since the proxy statement. Filing ↗
109Section 02, PERCEPTIVE ADVISORS LLC 2024-02-20Form 42024-02-210001062993-24-003957Insider equity transaction reported since the proxy statement. Filing ↗
110Section 02, N. Anthony Coles 2024-02-29Form 42024-03-040000950170-24-025036Insider equity transaction reported since the proxy statement. Filing ↗
111Section 02, N. Anthony Coles 2024-02-29Form 42024-03-040000950170-24-025036Insider equity transaction reported since the proxy statement. Filing ↗
112Section 02, N. Anthony Coles 2024-02-29Form 42024-03-040000950170-24-025036Insider equity transaction reported since the proxy statement. Filing ↗
113Section 02, N. Anthony Coles 2024-03-04Form 42024-03-060000950170-24-027156Insider equity transaction reported since the proxy statement. Filing ↗
114Section 02, N. Anthony Coles 2024-03-04Form 42024-03-060000950170-24-027156Insider equity transaction reported since the proxy statement. Filing ↗
115Section 02, N. Anthony Coles 2024-03-04Form 42024-03-060000950170-24-027156Insider equity transaction reported since the proxy statement. Filing ↗
116Section 02, N. Anthony Coles 2024-04-01Form 42024-04-030000950170-24-041073Insider equity transaction reported since the proxy statement. Filing ↗
117Section 02, N. Anthony Coles 2024-04-01Form 42024-04-030000950170-24-041073Insider equity transaction reported since the proxy statement. Filing ↗
118Section 02, N. Anthony Coles 2024-04-01Form 42024-04-030000950170-24-041073Insider equity transaction reported since the proxy statement. Filing ↗
119Section 02, N. Anthony Coles 2024-05-10Form 42024-05-140000950170-24-059788Insider equity transaction reported since the proxy statement. Filing ↗
120Section 02, N. Anthony Coles 2024-05-10Form 42024-05-140000950170-24-059788Insider equity transaction reported since the proxy statement. Filing ↗
121Section 02, N. Anthony Coles 2024-05-10Form 42024-05-140000950170-24-059788Insider equity transaction reported since the proxy statement. Filing ↗
122Section 02, N. Anthony Coles 2024-06-03Form 42024-06-050000950170-24-069284Insider equity transaction reported since the proxy statement. Filing ↗
123Section 02, N. Anthony Coles 2024-06-03Form 42024-06-050000950170-24-069284Insider equity transaction reported since the proxy statement. Filing ↗
124Section 02, N. Anthony Coles 2024-06-03Form 42024-06-050000950170-24-069284Insider equity transaction reported since the proxy statement. Filing ↗
125Section 02, Ruth Mckernan 2024-06-05Form 42024-06-070000950170-24-070692Insider equity transaction reported since the proxy statement. Filing ↗
126Section 02, Gabrielle Sulzberger 2024-06-05Form 42024-06-070000950170-24-070694Insider equity transaction reported since the proxy statement. Filing ↗
127Section 02, Douglas E. Giordano 2024-06-05Form 42024-06-070000950170-24-070724Insider equity transaction reported since the proxy statement. Filing ↗
128Section 02, Norbert G. Riedel 2024-06-05Form 42024-06-070000950170-24-070725Insider equity transaction reported since the proxy statement. Filing ↗
129Section 02, Deval L. Patrick 2024-06-05Form 42024-06-070000950170-24-070734Insider equity transaction reported since the proxy statement. Filing ↗
130Section 02, Marijn E. Dekkers 2024-06-05Form 42024-06-070000950170-24-070735Insider equity transaction reported since the proxy statement. Filing ↗
131Section 02, Adam Koppel 2024-06-05Form 42024-06-070000950170-24-070855Insider equity transaction reported since the proxy statement. Filing ↗
132Section 02, N. Anthony Coles 2024-06-05Form 42024-06-070000950170-24-070736Insider equity transaction reported since the proxy statement. Filing ↗
133Section 02, Christopher R. Gordon 2024-06-05Form 42024-06-070000950170-24-070908Insider equity transaction reported since the proxy statement. Filing ↗
134Section 02, N. Anthony Coles 2024-07-01Form 42024-07-030000950170-24-081490Insider equity transaction reported since the proxy statement. Filing ↗
135Section 02, N. Anthony Coles 2024-07-01Form 42024-07-030000950170-24-081490Insider equity transaction reported since the proxy statement. Filing ↗
136Section 02, N. Anthony Coles 2024-07-01Form 42024-07-030000950170-24-081490Insider equity transaction reported since the proxy statement. Filing ↗
137Section 02, N. Anthony Coles 2024-08-01Form 42024-08-050000950170-24-090789Insider equity transaction reported since the proxy statement. Filing ↗
138Section 02, N. Anthony Coles 2024-08-01Form 42024-08-050000950170-24-090789Insider equity transaction reported since the proxy statement. Filing ↗
139Section 02, N. Anthony Coles 2024-08-01Form 42024-08-050000950170-24-090789Insider equity transaction reported since the proxy statement. Filing ↗
140Section 02, Mark Bodenrader 2024-08-01Form 42024-08-050000950170-24-090801Insider equity transaction reported since the proxy statement. Filing ↗
141Section 02, Mark Bodenrader 2024-08-01Form 42024-08-050000950170-24-090801Insider equity transaction reported since the proxy statement. Filing ↗
142Section 02, Mark Bodenrader 2024-08-01Form 42024-08-050000950170-24-090801Insider equity transaction reported since the proxy statement. Filing ↗
143Section 02, John Renger 2024-08-01Form 42024-08-050000950170-24-090830Insider equity transaction reported since the proxy statement. Filing ↗
144Section 02, John Renger 2024-08-01Form 42024-08-050000950170-24-090830Insider equity transaction reported since the proxy statement. Filing ↗
145Section 02, John Renger 2024-08-01Form 42024-08-050000950170-24-090830Insider equity transaction reported since the proxy statement. Filing ↗
146Section 02, John Renger 2024-08-01Form 42024-08-050000950170-24-090830Insider equity transaction reported since the proxy statement. Filing ↗
147Section 02, N. Anthony Coles 2024-08-01Form 42024-08-050000950170-24-090789Insider equity transaction reported since the proxy statement. Filing ↗
148Section 02, Paul D. Burgess 2024-08-01Form 42024-08-050000950170-24-090787Insider equity transaction reported since the proxy statement. Filing ↗
149Section 02, Paul D. Burgess 2024-08-01Form 42024-08-050000950170-24-090787Insider equity transaction reported since the proxy statement. Filing ↗
150Section 02, Paul D. Burgess 2024-08-01Form 42024-08-050000950170-24-090787Insider equity transaction reported since the proxy statement. Filing ↗
151Section 02, Deval L. Patrick 2024-08-01Form 42024-08-050000950170-24-090790Insider equity transaction reported since the proxy statement. Filing ↗
152Section 02, Deval L. Patrick 2024-08-01Form 42024-08-050000950170-24-090790Insider equity transaction reported since the proxy statement. Filing ↗
153Section 02, Deval L. Patrick 2024-08-01Form 42024-08-050000950170-24-090790Insider equity transaction reported since the proxy statement. Filing ↗
154Section 02, Norbert G. Riedel 2024-08-01Form 42024-08-050000950170-24-090806Insider equity transaction reported since the proxy statement. Filing ↗
155Section 02, Norbert G. Riedel 2024-08-01Form 42024-08-050000950170-24-090806Insider equity transaction reported since the proxy statement. Filing ↗
156Section 02, Norbert G. Riedel 2024-08-01Form 42024-08-050000950170-24-090806Insider equity transaction reported since the proxy statement. Filing ↗
157Section 02, Susan ALTSCHULLER 2024-08-01Form 42024-08-050000950170-24-090813Insider equity transaction reported since the proxy statement. Filing ↗
158Section 02, Susan ALTSCHULLER 2024-08-01Form 42024-08-050000950170-24-090813Insider equity transaction reported since the proxy statement. Filing ↗
159Section 02, Susan ALTSCHULLER 2024-08-01Form 42024-08-050000950170-24-090813Insider equity transaction reported since the proxy statement. Filing ↗
160Section 02, Marijn E. Dekkers 2024-08-01Form 42024-08-050000950170-24-090815Insider equity transaction reported since the proxy statement. Filing ↗
161Section 02, Marijn E. Dekkers 2024-08-01Form 42024-08-050000950170-24-090815Insider equity transaction reported since the proxy statement. Filing ↗
162Section 02, Marijn E. Dekkers 2024-08-01Form 42024-08-050000950170-24-090815Insider equity transaction reported since the proxy statement. Filing ↗
163Section 02, Marijn E. Dekkers 2024-08-01Form 42024-08-050000950170-24-090815Insider equity transaction reported since the proxy statement. Filing ↗
164Section 02, Kathleen Tregoning 2024-08-01Form 42024-08-050000950170-24-090822Insider equity transaction reported since the proxy statement. Filing ↗
165Section 02, Kathleen Tregoning 2024-08-01Form 42024-08-050000950170-24-090822Insider equity transaction reported since the proxy statement. Filing ↗
166Section 02, Kathleen Tregoning 2024-08-01Form 42024-08-050000950170-24-090822Insider equity transaction reported since the proxy statement. Filing ↗
167Section 02, Kenneth DiPietro 2024-08-01Form 42024-08-050000950170-24-090827Insider equity transaction reported since the proxy statement. Filing ↗
168Section 02, Kenneth DiPietro 2024-08-01Form 42024-08-050000950170-24-090827Insider equity transaction reported since the proxy statement. Filing ↗
169Section 02, Kenneth DiPietro 2024-08-01Form 42024-08-050000950170-24-090827Insider equity transaction reported since the proxy statement. Filing ↗
170Section 02, Gabrielle Sulzberger 2024-08-01Form 42024-08-050000950170-24-090833Insider equity transaction reported since the proxy statement. Filing ↗
171Section 02, Gabrielle Sulzberger 2024-08-01Form 42024-08-050000950170-24-090833Insider equity transaction reported since the proxy statement. Filing ↗
172Section 02, Gabrielle Sulzberger 2024-08-01Form 42024-08-050000950170-24-090833Insider equity transaction reported since the proxy statement. Filing ↗
173Section 02, Scott Akamine 2024-08-01Form 42024-08-050000950170-24-090841Insider equity transaction reported since the proxy statement. Filing ↗
174Section 02, Scott Akamine 2024-08-01Form 42024-08-050000950170-24-090841Insider equity transaction reported since the proxy statement. Filing ↗
175Section 02, Scott Akamine 2024-08-01Form 42024-08-050000950170-24-090841Insider equity transaction reported since the proxy statement. Filing ↗
176Section 02, Ruth Mckernan 2024-08-01Form 42024-08-050000950170-24-090842Insider equity transaction reported since the proxy statement. Filing ↗
177Section 02, Ruth Mckernan 2024-08-01Form 42024-08-050000950170-24-090842Insider equity transaction reported since the proxy statement. Filing ↗
178Section 02, Ruth Mckernan 2024-08-01Form 42024-08-050000950170-24-090842Insider equity transaction reported since the proxy statement. Filing ↗
179Section 02, Ronald C. Renaud JR 2024-08-01Form 42024-08-050000950170-24-090851Insider equity transaction reported since the proxy statement. Filing ↗
180Section 02, Ronald C. Renaud JR 2024-08-01Form 42024-08-050000950170-24-090851Insider equity transaction reported since the proxy statement. Filing ↗
181Section 02, Ronald C. Renaud JR 2024-08-01Form 42024-08-050000950170-24-090851Insider equity transaction reported since the proxy statement. Filing ↗
182Section 02, Ronald C. Renaud JR 2024-08-01Form 42024-08-050000950170-24-090851Insider equity transaction reported since the proxy statement. Filing ↗
183Section 02, Ronald C. Renaud JR 2024-08-01Form 42024-08-050000950170-24-090851Insider equity transaction reported since the proxy statement. Filing ↗
184Section 02, Douglas E. Giordano 2024-08-01Form 42024-08-050000950170-24-090853Insider equity transaction reported since the proxy statement. Filing ↗
185Section 02, Douglas E. Giordano 2024-08-01Form 42024-08-050000950170-24-090853Insider equity transaction reported since the proxy statement. Filing ↗
186Section 02, Douglas E. Giordano 2024-08-01Form 42024-08-050000950170-24-090853Insider equity transaction reported since the proxy statement. Filing ↗
187Section 02, Raymond Sanchez 2024-08-01Form 42024-08-050000950170-24-090861Insider equity transaction reported since the proxy statement. Filing ↗
188Section 02, Raymond Sanchez 2024-08-01Form 42024-08-050000950170-24-090861Insider equity transaction reported since the proxy statement. Filing ↗
189Section 02, Raymond Sanchez 2024-08-01Form 42024-08-050000950170-24-090861Insider equity transaction reported since the proxy statement. Filing ↗
190Section 02, Adam Koppel 2024-08-01Form 42024-08-050000950170-24-090903Insider equity transaction reported since the proxy statement. Filing ↗
191Section 02, Adam Koppel 2024-08-01Form 42024-08-050000950170-24-090903Insider equity transaction reported since the proxy statement. Filing ↗
192Section 02, Adam Koppel 2024-08-01Form 42024-08-050000950170-24-090903Insider equity transaction reported since the proxy statement. Filing ↗
193Section 02, Adam Koppel 2024-08-01Form 42024-08-050000950170-24-090903Insider equity transaction reported since the proxy statement. Filing ↗
194Section 02, Christopher R. Gordon 2024-08-01Form 42024-08-050000950170-24-090908Insider equity transaction reported since the proxy statement. Filing ↗
195Section 02, Christopher R. Gordon 2024-08-01Form 42024-08-050000950170-24-090908Insider equity transaction reported since the proxy statement. Filing ↗
196Section 02, Christopher R. Gordon 2024-08-01Form 42024-08-050000950170-24-090908Insider equity transaction reported since the proxy statement. Filing ↗
197Section 02, Christopher R. Gordon 2024-08-01Form 42024-08-050000950170-24-090908Insider equity transaction reported since the proxy statement. Filing ↗
198Section 02, BAIN CAPITAL INVESTORS LLC 2024-08-01Form 42024-08-050000950170-24-090909Insider equity transaction reported since the proxy statement. Filing ↗
199Section 02, PFIZER INC 2024-08-01Form 42024-08-050000078003-24-000169Insider equity transaction reported since the proxy statement. Filing ↗
200Section 06, 2023 voteForm 8-K2023-06-080001193125-23-163542Item 5.07 · say-on-pay result. As reported: 99.59% (votes for as printed: 148,773,111). Filing ↗
201Section 06, 2022 voteForm 8-K2022-06-150001193125-22-174248Item 5.07 · say-on-pay result. As reported: 99.66% (votes for as printed: 115,000,333). Filing ↗
202Section 06, 2021 voteForm 8-K2021-06-160001193125-21-192224Item 5.07 · say-on-pay result. As reported: —. Filing ↗
203Section 01 trend, Δ column (computed)Computed——Δ = current-FY total − prior-FY total per named officer.machine: formula: Δ = FY(n) − FY(n−1)
204Section 03b vehicle mix (computed)Computed——RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio
205Section 09b board cost (computed)Computed——Cash 607,246 + equity 0 + all other 0 = 607,246, summed across the director compensation table rows.machine: formula: Σ = 607,246
206BridgeBio Pharma, Section 10b CEO totalDEF 14A2026-04-240001140361-26-016723CEO total compensation as printed in BridgeBio Pharma's own proxy. As printed: 14,944,585. Filing ↗machine: r2 · c21 · span 527521–527531
207Neurocrine Biosciences, Section 10b CEO totalDEF 14A2026-04-150000914475-26-000015CEO total compensation as printed in Neurocrine Biosciences's own proxy. As printed: 13,448,935. Filing ↗machine: t50 · r4 · c7 · span 847947–847957
208Cerevel Therapeutics Holdings (subject), Section 10b CEO totalDEF 14A2023-04-280000950170-23-015766CEO total compensation as printed in Cerevel Therapeutics Holdings's own proxy. As printed: 11,225,426. Filing ↗machine: t23 · r2 · c29 · span 1010006–1010016
209Karuna Therapeutics, Section 10b CEO totalDEF 14A2023-04-270000950170-23-014979CEO total compensation as printed in Karuna Therapeutics's own proxy. As printed: 11,224,103. Filing ↗machine: r2 · c25 · span 856684–856694
210Axsome Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177610CEO total compensation as printed in Axsome Therapeutics's own proxy. As printed: 10,283,492. Filing ↗machine: t51 · r2 · c27 · span 900236–900246
211Arcus Biosciences, Section 10b CEO totalDEF 14A2026-04-210001724521-26-000025CEO total compensation as printed in Arcus Biosciences's own proxy. As printed: 9,656,813. Filing ↗machine: r2 · c48 · span 403740–403749
212Sage Therapeutics, Section 10b CEO totalDEF 14A2025-04-240000950170-25-058060CEO total compensation as printed in Sage Therapeutics's own proxy. As printed: 7,112,589. Filing ↗machine: r4 · c28 · span 1143784–1143793
213Arvinas, Section 10b CEO totalDEF 14A2026-04-290001628280-26-028156CEO total compensation as printed in Arvinas's own proxy. As printed: 6,534,127. Filing ↗machine: t20 · r3 · c22 · span 471921–471930
214Allogene Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001628280-26-028948CEO total compensation as printed in Allogene Therapeutics's own proxy. As printed: 6,136,093. Filing ↗machine: r2 · c54 · span 451014–451023
215Replimune Group, Section 10b CEO totalDEF 14A2026-07-290001104659-26-087650CEO total compensation as printed in Replimune Group's own proxy. As printed: 5,845,982. Filing ↗machine: r1 · c41 · span 430765–430774
216Zymeworks, Section 10b CEO totalDEF 14A2025-11-100001193125-25-274338CEO total compensation as printed in Zymeworks's own proxy. As printed: 5,253,616. Filing ↗machine: r2 · c30 · span 541437–541446
217Intellia Therapeutics, Section 10b CEO totalDEF 14A2026-04-300001193125-26-197283CEO total compensation as printed in Intellia Therapeutics's own proxy. As printed: 5,063,899. Filing ↗machine: r2 · c25 · span 749290–749299
218Denali Therapeutics, Section 10b CEO totalDEF 14A2026-04-210001714899-26-000054CEO total compensation as printed in Denali Therapeutics's own proxy. As printed: 4,751,515. Filing ↗machine: t25 · r2 · c25 · span 469605–469614
219Fate Therapeutics, Section 10b CEO totalDEF 14A2026-04-240001193125-26-177094CEO total compensation as printed in Fate Therapeutics's own proxy. As printed: 2,248,568. Filing ↗machine: r2 · c31 · span 391551–391560
220Alector, Section 10b CEO totalDEF 14A2026-04-280001193125-26-186928CEO total compensation as printed in Alector's own proxy. As printed: 1,995,018. Filing ↗machine: span 1038665–1038674
221Section 10a, Neurocrine Biosciences reciprocityDEF 14A—0000914475-26-000015Neurocrine Biosciences's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
222Section 10a, Intellia Therapeutics reciprocityDEF 14A—0001193125-26-197283Intellia Therapeutics's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
223Section 10a, Karuna Therapeutics reciprocityDEF 14A—0000950170-23-014979Karuna Therapeutics names Cerevel Therapeutics Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗
224Section 10a, Allogene Therapeutics reciprocityDEF 14A—0001628280-26-028948Allogene Therapeutics's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
225Section 10a, Axsome Therapeutics reciprocityDEF 14A—0001193125-26-177610Axsome Therapeutics's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
226Section 10a, BridgeBio Pharma reciprocityDEF 14A—0001140361-26-016723BridgeBio Pharma's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
227Section 10a, Denali Therapeutics reciprocityDEF 14A—0001714899-26-000054Denali Therapeutics's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
228Section 10a, Sage Therapeutics reciprocityDEF 14A—0000950170-25-058060Sage Therapeutics names Cerevel Therapeutics Holdings in its own disclosed peer group (read from its most recent proxy). Filing ↗
229Section 10a, Arvinas reciprocityDEF 14A—0001628280-26-028156Arvinas's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗
230Section 10a, Alector reciprocityDEF 14A—0001193125-26-186928Alector's most recent proxy was read; its disclosed peer group does not include Cerevel Therapeutics Holdings. Filing ↗

The Pay Desk — the free weekly executive pay briefing, one company at a time, every number traceable to a public filing.

You'll confirm on The Pay Desk's sign-up page.

How this page was built: the Cerevel Therapeutics Holdings filed document, accession 0000950170-23-015766. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2023.

Velarion Company Intelligence — the platform behind this brief: every company, every peer set, every year.

  • This brief is the per-company record — free, complete, and cited.
  • See every company in your universe the same way: a 3-day full-access trial of Velarion Company Intelligence, no card required.
  • Go further with a 30-day Platform Pilot — $5,000, fully creditable against a subscription.
  • Velarion Company Intelligence: Member $25,000/year (one industry) or Advisor $75,000/year (all industries). Annual billing.

Compensation topics — plain-English guides to executive and board pay, benchmarking, the CEO pay ratio, and say-on-pay. Every live product and its price is on the pricing page.